百时美施贵宝陈思渊：让创新惠及更多患者

第一财经11-29

今年以来，创新药赛道持续受到政策关注与市场瞩目。我国创新药市场的发展也给跨国药企带来更多机遇。加码中国创新，跨国药企如何布局？第一财经《首席评论》近期专访了百时美施贵宝副总裁、中国及亚洲区域市场总经理陈思渊，共同探讨相关话题。第一财经：百时美施贵宝在2020年提出了 “中国2030战略”，目前进展如何？陈思渊：百时美施贵宝“中国2030战略”的目标是把更多的创新药物在第一时间带给中国患者，在中国...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2487303541?lang=zh_CN&edition=full","thumbnail":"https://inews.gtimg.com/om_ls/OQpoyRGS28dQcmlWpmGRSBOAvtDCH70YKrPQ2QEcS_o3AAA_294195/0","is_english":false,"pubTime":"2024-11-29 11:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2487303541","market":"hk","top_or_hot":-1,"title":"百时美施贵宝陈思渊：让创新惠及更多患者","media":"第一财经","content":"<div>\n<p>今年以来，创新药赛道持续受到政策关注与市场瞩目。我国创新药市场的发展也给跨国药企带来更多机遇。加码中国创新，跨国药企如何布局？第一财经《首席评论》近期专访了百时美施贵宝副总裁、中国及亚洲区域市场总经理陈思渊，共同探讨相关话题。第一财经：百时美施贵宝在2020年提出了 “中国2030战略”，目前进展如何？陈思渊：百时美施贵宝“中国2030战略”的目标是把更多的创新药物在第一时间带给中国患者，在中国...</p>\n\n<a href=\"https://new.qq.com/rain/a/20241129A03HSV00\">网页链接</a>\n\n</div>\n","source":"tencent_tech","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百时美施贵宝陈思渊：让创新惠及更多患者</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百时美施贵宝陈思渊：让创新惠及更多患者\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-29 11:25 北京时间&nbsp;&nbsp;&nbsp;<a href=https://new.qq.com/rain/a/20241129A03HSV00><strong>第一财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>今年以来，创新药赛道持续受到政策关注与市场瞩目。我国创新药市场的发展也给跨国药企带来更多机遇。加码中国创新，跨国药企如何布局？第一财经《首席评论》近期专访了百时美施贵宝副总裁、中国及亚洲区域市场总经理陈思渊，共同探讨相关话题。第一财经：百时美施贵宝在2020年提出了 “中国2030战略”，目前进展如何？陈思渊：百时美施贵宝“中国2030战略”的目标是把更多的创新药物在第一时间带给中国患者，在中国...</p>\n\n<a href=\"https://new.qq.com/rain/a/20241129A03HSV00\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1868836757.USD","symbol_name":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","start_time":0,"source_url":"https://new.qq.com/rain/a/20241129A03HSV00","article_id":"2487303541","we_media_id":null,"thumbnails":["https://inews.gtimg.com/om_ls/OQpoyRGS28dQcmlWpmGRSBOAvtDCH70YKrPQ2QEcS_o3AAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241129A03HSV00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2487303541","pubTimestamp":1732850742,"columns":[],"sourceInfo":{"source_id":"tencent_tech","name":"腾讯科技"},"weMediaInfo":null,"summary":"今年以来，创新药赛道持续受到政策关注与市场瞩目。我国创新药市场的发展也给跨国药企带来更多机遇。加码中国创新，跨国药企如何布局？第一财经《首席评论》近期专访了百时美施贵宝副总裁、中国及亚洲区域市场总经理陈思渊，共同探讨相关话题。第一财经：百时美施贵宝在2020年提出了 “中国2030战略”，目前进展如何？陈思...","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","BK4559":"巴菲特持仓","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","BK4588":"碎股","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BMY":"施贵宝","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4581":"高盛持仓","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","BK4532":"文艺复兴科技持仓","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU0237698245.USD":"富达环球地产基金A","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4585":"ETF&股票定投概念","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4534":"瑞士信贷持仓","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4007":"制药","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC"},"translate_title":"Bristol-Myers Squibb Chen Siyuan: Let innovation benefit more patients","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":1},"content_text":"今年以来，创新药赛道持续受到政策关注与市场瞩目。我国创新药市场的发展也给跨国药企带来更多机遇。加码中国创新，跨国药企如何布局？第一财经《首席评论》近期专访了百时美施贵宝副总裁、中国及亚洲区域市场总经理陈思渊，共同探讨相关话题。第一财经：百时美施贵宝在2020年提出了 “中国2030战略”，目前进展如何？陈思渊：百时美施贵宝“中国2030战略”的目标是把更多的创新药物在第一时间带给中国患者，在中国扩大这些药物的患者可及性，同时通过合作探索更多源于中国的创新。当然，我们也正在通过人才战略，致力于成为肿瘤学、血液学、免疫学和心血管这些核心疾病领域的创新领导者。过去几年，从研发角度来说，百时美施贵宝中国已实现与全球同步开展III期临床研究。而在中国迫切未被满足的疾病领域，还将逐步同步参与到全球的早期开发中。注册申报方面，我们的目标是，所有产品都能实现中国与全球的同步申报。今年，我们在中国上市了两款“同类首创”的创新药，分别是用于治疗中重度斑块状银屑病的口服TYK2变构抑制剂氘可来昔替尼片以及用于治疗梗阻性肥厚型心肌病的玛伐凯泰。在患者可及方面，一方面，我们始终以最大的诚意、尽最大努力推动百时美施贵宝的创新药进入医保。刚刚提到的玛伐凯泰、氘可来昔替尼片都已被纳入了最新版国家医保目录，而用于治疗β-地中海贫血的罗特西普也在今年成功实现了医保续约。另一方面，我们也在创新支付模式、早期准入等方面进行了深入的探索，希望让更多患者更早地获益于我们的创新药物。第一财经：玛伐凯泰纳入医保对于患者来说意味着什么？陈思渊：梗阻性肥厚型心肌病患者的平均年龄在四五十岁，这些患者往往承担着重要的社会与家庭责任。疾病所导致的急慢性并发症不仅影响了患者的生活质量，也因为需要持续的疾病管理，为家庭和社会带来了沉重的负担。玛伐凯泰被纳入医保不仅能够降低患者的用药负担，也体现了政府提高优质医疗资源可及性的决心与努力。我们将积极与各方携手，支持支付方和当地政府的工作，尽快实现药物在各省市的医保可及，让更多中国患者可持续地获益于这款创新药物。第一财经：我们了解到玛伐凯泰是百时美施贵宝业务发展(BD)的成果之一。创新药的不确定性非常高，你们选择BD合作时的核心考量是什么？在中国，你们又是通过哪些方式来拓展创新合作的？陈思渊：我们所有的工作都是为了满足患者未满足的需求，致力于在核心治疗领域带来更多同类首个(First-in-Class)或者同类最佳(Best-in-Class)的创新治疗选择。我们希望能够通过双赢的合作，使更多患者获益。因此，对于百时美施贵宝来说，阶段、规模都不是关键，信任与共识才是合作的基础。在评估和选择战略合作时，我们主要会围绕三个方面进行评估和考虑：一是看创新资产所在的治疗领域是否契合我们的战略，即百时美施贵宝的核心治疗领域；二是评估创新资产是否具备了强大的科学实力和创新突破的潜力；三是看其是否能够为患者带来长期价值。正是通过成功的BD，我们获得了在中国及其他部分亚洲市场开发和商业化迈凡妥的独家权利。此外，我们也希望搭建更大的平台，让整个创新生态系统的相关方有机会探讨、发掘更多合作机会。我们已经连续两年在中国举办百时美施贵宝中国合作周，在今年的活动期间，公司董事会主席、首席执行官博科思（Christopher Boerner）亲自带队来到中国，出席了“中国合作周·创新日论坛”活动，充分表达了百时美施贵宝与各方“通过合作寻找并推动最佳的科学创新，惠及更多患者”的诚意与决心。第一财经：展望“中国2030战略”后半程，百时美施贵宝将如何聚焦下一步工作，确保这一战略能够顺利完成？陈思渊：我们会继续立足于我们的核心竞争力——创新，围绕同步研发、患者可及、创新合作以及人才发展等，坚定不移地加速执行，从而让更多创新药物更快地惠及更多中国患者。查看原图 61K","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2487303541"}